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Two chiral methodologies were developed by Capillary Electrophoresis (CE) with 24 
UV and Mass Spectrometry (MS) detection to ensure the quality control of the drug 25 
duloxetine, commercialized as a pure enantiomer. Both methods were optimized to 26 
achieve a high baseline enantioresolution (Rs > 2) and an acceptable precision (RSD 27 
values < 5 % for instrumental repeatability and < 10 % for intermediate precision). In 28 
addition to allow the unequivocal identification of duloxetine enantiomers, the CE-MS 29 
method improved the sensitivity with respect to the use of CE-UV (LOD 200 ng/mL by 30 
CE-UV and 20 ng/mL by CE-MS) enabling to detect 0.02 % of duloxetine enantiomeric 31 
impurity. This is the lowest LOD value ever reported for this drug, being this work the 32 
first one enabling to accomplish with the ICH guidelines requirements. The developed 33 
methods were validated and applied for the first time to the analysis of four 34 
pharmaceutical formulations. The content of R-duloxetine in all these samples was below 35 
the detection limit and the amount of S-duloxetine was in good agreement with the labeled 36 
content, obtaining results by the two methods that did not differ significantly (p-values > 37 
0.05). 38 
 39 
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1. Introduction 43 
 44 
Chirality acquires special relevance in the pharmaceutical industry since drug 45 
properties are strong dependent on the ingested enantiomer as a result of the inherent 46 
enantioselectivity of the biological processes. Due to the potentially different bioactivity 47 
of the enantiomers of a chiral drug, it is mandatory for the pharmaceutical laboratories to 48 
justify the commercialization of a new drug, either as a pure enantiomer or as a racemic 49 
mixture. Therefore, a rigorous quality control must be carried out to regulate the drug 50 
enantiomeric impurities present in a pharmaceutical formulation, especially if they have 51 
adverse effects. 52 
As many pharmaceutical compounds, duloxetine ((+)-(S)-N-methyl-γ-(1-53 
naphthalenyloxy)-3-(2-thiopene)-propanamine) is a chiral drug. Both enantiomers of 54 
duloxetine are potent norepinephrine and serotonin reuptake inhibitors, although the S-55 
enantiomer was found to be slightly more potent [1]. Since this drug is commercialized 56 
as a pure enantiomer in the treatment of major depressive disorder [2], chiral 57 
methodologies need to be developed to ensure the quality control of its optical purity. 58 
These methodologies must, on the one hand, separate the desired enantiomers of a chiral 59 
drug and, on the other hand, detect low amounts of the enantiomeric impurities (the 60 
International Conference on Harmonisation (ICH) dictates that a method must be able to 61 
detect amounts of a determined impurity lower than 0.1 % [3]).  62 
The separation and study of duloxetine enantiomers have been reported by HPLC 63 
and CE with UV detection. Regarding HPLC, Rane et al. [4] developed a chiral 64 
methodology employing a chiral stationary phase (CSP) based on amylose detecting 250 65 
ng/mL of duloxetine impurity, which eluted in first place. Yang et al. [5] described two 66 
HPLC methods, one employing a vancomycin CSP and the other using (2-67 
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hydroxypropyl)-β-CD (HP-β-CD) as additive in the mobile phase. In both cases, the 68 
enantiomeric impurity of duloxetine was the last to elute making it harder to be detected 69 
in presence of high amounts of the major enantiomer. CE methods have also been 70 
described. Some authors reported methods employing glycogen based selectors [6, 7] and 71 
erythromycin lactobionate [8, 9] resulting in analysis times from 15 to 60 min. Rickard et 72 
al. reported an acceptable duloxetine enantioseparation by means of HP-β-CD in 25 min 73 
detecting up to 0.2 % of enantiomeric impurity as it migrated in first place [10, 11]. This 74 
is, so far, the only LOD reported for R-duloxetine in the bibliography; nevertheless, it is 75 
not in agreement with the ICH guidelines requirements [3]. This remarks the necessity to 76 
develop more sensitive methods to be able to determine duloxetine enantiomers in 77 
pharmaceutical formulations. 78 
CE is one of the most relevant analytical techniques used in chiral separation since 79 
it offers many advantages such as high resolution power, low reagents and sample 80 
consumption, and high flexibility given the possibility to easily modify the chiral selector 81 
added to the BGE. In addition, CE can be coupled to MS to combine the advantages of 82 
CE in chiral analysis with the MS potential to identify unknown chiral compounds with 83 
unambiguous assignment and to give structural information [12, 13]. The main problem 84 
of the chiral CE-MS coupling is the contamination of the ionization source as a result of 85 
the entrance of non-volatile chiral selectors, which produces a loss of the ionization 86 
efficiency and a decrease in the detection sensitivity [14, 15]. Although some works 87 
demonstrate no significant decrease in the sensitivity when low concentrations of the 88 
chiral selector are employed [13, 14, 16], different approaches and strategies have been 89 
broadly employed to solve this problem. These strategies include the use of compatible 90 
chiral selectors in EKC or CSPs in Capillary Electrochromatography (CEC), or counter 91 
migration and partial filling techniques (PFT) [12, 13, 15, 17-19].  92 
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The aim of this work was the development of two CE methodologies using UV and 93 
MS detection for the enantioseparation of duloxetine, along with their validation to 94 
establish the content of duloxetine and its enantiomeric impurity in different 95 
pharmaceutical formulations.  96 
 97 
2. Materials and methods 98 
 99 
2.1. Reagents and samples 100 
 All reagents were of analytical grade. Ortho-phosphoric acid 85 % (v/v), dimethyl 101 
sulfoxide (DMSO), and sodium hydroxide were purchased from Merck (Darmstadt, 102 
Germany). Methanol was obtained from Scharlau Chemie (Barcelona, Spain) and formic 103 
acid, and ammonium hydroxide from Sigma (St. Louis, MO, USA). The employed water 104 
was MilliQ quality (Millipore, Bedford, MA, USA). β-CD; methyl-β-CD (M--CD) (DS 105 
1.7-1.9); HP-β-CD (DS ~4.2); 2,6-di-O-methyl-β-CD and 2,3,6-tri-O-methyl-β-CD were 106 
acquired in Fluka (Buchs, Switzerland). Acetyl-β-CD; (2-hydroxybutenyl)-β-CD (HB-β-107 
CD); 2,3,6-tri-O-acetyl-β-CD; γ-CD, acetyl-γ-CD (A-γ-CD); methyl-γ-CD (M-γ-CD) 108 
(DS ~12), (2-hydroxy)-butenyl-γ-CD (DS ~4.5), (2-hydroxy)-butenyl-γ-CD (DS ~3.2) 109 
and 2,3,6-tri-O-acetyl γ-CD were purchased from Cyclolab (Budapest, Hungary). M-β-110 
CD (DS 10.5-14.7) was bought in Sigma-Aldrich (St. Louis, MO, USA).  111 
 (R, S)-Duloxetine HCl, (R)-Duloxetine HCl and (S)-Duloxetine HCl were 112 
purchased from IS Chemical Technology (Shanghai, China). The commercial 113 
pharmaceutical formulations were acquired in pharmacies from Madrid (Spain). 114 
According to the labeled data, they contained 30 mg of duloxetine per capsule.  115 
 116 
2.2. CE-UV conditions 117 
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 Electrophoretic experiments were carried out on a HP 3DCE system from Agilent 118 
Technologies (Palo Alto, CA, USA) with a diode array detector (DAD). The 119 
electrophoretic system was controlled by HP 3DCE ChemStation software included the 120 
data collection and analysis. BGE employed in the CE-UV experiments consisted on 150 121 
mM phosphate buffer (pH 3.0) containing 0.5 % (w/v) of HP-β-CD. Separations were 122 
performed in an uncoated fused-silica capillary of 50 µm I.D. and a total length of 64.5 123 
cm, acquired from Polymicro Technologies (Phoenix, AZ, USA) at 30 kV (positive 124 
polarity) and 20 ºC. Injections were carried out applying 50 mbar for 20 s. Detector 125 
parameters were as follows: a response time of 1.0 s and a wavelength of 220 nm 126 
(bandwidth 35 nm) including a reference wavelength of 375 nm (bandwidth 100 nm). At 127 
the beginning of each working day the capillary was flushed with buffer solution for 10 128 
min and at the end of the day it was flushed with MilliQ water for 5 min. In order to 129 
ensure the repeatability between injections, the capillary was flushed with DMSO for 2 130 
min, buffer solution for 3 min and BGE for 1 min 131 
 132 
2.3. CE-MS conditions 133 
CE-MS analysis were performed in a HP3DCE instrument (Agilent Technologies, 134 
Palo Alto, CA, USA) coupled through an orthogonal coaxial sheath interface (model 135 
G1607A from Agilent Technologies, Palo Alto, CA, USA) to the Electrospray Ionization 136 
(ESI) source of an Ion Trap (IT) mass spectrometer (model AmaZon SL from Bruker 137 
Daltonics, Bremen, Germany) for MS detection. For MS control and data analysis, a 138 
TrapControl Software 7.0 for AmaZon was used. BGE employed in the CE-MS 139 
experiments consisted of 150 mM ammonium formate buffer (pH 3.0). The separation 140 
was achieved in an uncoated fused-silica capillary of 104 cm and 50 µm I.D., at 30 kV 141 
(positive polarity) and 15 ºC. Injections were performed applying 50 mbar for 5 s. 142 
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Between analysis, the capillary was flushed by applying 1 bar with DMSO for 4 min, 143 
BGE solution for 5 min and BGE with 0.5 % (w/v) of HP-β-CD during 1 min (38 % of 144 
total capillary length).  145 
Operating MS conditions consisted on a sheath liquid composition of 80:20 (v/v) 146 
methanol/water with 0.1 % (v/v) of formic acid at a flow rate of 3.3 µL/min by a syringe 147 
pump (Hamilton, USA). The nebulizer and the drying gas conditions were 3 psi N2 and 5 148 
L/min N2 at 200 ºC. The mass spectrometer operated with the ESI source in the positive 149 
ion mode at -4.5 kV with an end plate of -500 V. The ion optical parameters were tuned 150 
in the “expert mode” and the capillary exit value was optimized to 57 V. In MS2 151 
experiments the Ion Charge Control (ICC) was activated with a target up to 100,000 ions 152 
using 50 ms of accumulation time and 3 averages. The m/z scanned range was from 100 153 
to 400 m/z in the “UltraScan” mode (32,000 (m/z)/s). The isolation width of the precursor 154 
ion (298.1 m/z) was set to 4.0 m/z. Its fragmentation was carried out by collision-induced 155 
dissociation with the helium present in the trap for 40 ms with a fragmentation amplitude 156 
of 0.5 V (with the “smart-frag” option deactivated) and a fragmentation width of 10 m/z. 157 
Extracted Ion Electrophoregrams (EIEs) were obtained extracting the product ion 153.8 158 
m/z with an extraction window of -0.3/+0.7 m/z using a smoothed option of the software 159 
(Gauss at 4 points). 160 
 161 
2.4. Preparation of stock and sample solutions 162 
Stock solutions of duloxetine were prepared in DMSO and then diluted with 163 
MilliQ water until desired concentration. Commercial pharmaceutical solutions were 164 
prepared by homogenizing the content of five capsules of the medicament and grinding 165 
it. The required amount for analysis of the grinded powder was dissolved in DMSO and 166 
centrifuged for 10 min with a rotational speed of 4000 rpm at 20 ºC. The supernatant was 167 
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taken and brought to a known volume. Afterwards, it was diluted to the required 168 
concentration employing MilliQ water.  169 
 170 
3. Results and discussion 171 
 172 
3.1. Development of a chiral methodology for the enantiomeric separation of duloxetine 173 
by CE with UV detection 174 
The first step in the method development was to choose a CD offering the best 175 
enantioselectivity and enantioresolution (Rs). Since duloxetine is a basic drug (pKa 9.7), 176 
an acidic BGE was employed in order to guarantee the presence of its protonated form.. 177 
A screening test with fifteen neutral CDs was carried out to further investigate the 178 
enantiodiscrimination of a high number of CDs towards duloxetine. Initial experimental 179 
conditions consisted on the corresponding CDs at 1.0 % (w/v) solved in a 50 mM 180 
phosphate buffer at pH 2.0. A capillary of 33.5 cm was employed working at a 181 
temperature of 20 ºC and a voltage of 15 kV. Among all the CDs investigated (see Section 182 
2.1), A-γ-CD, HB-β-CD, M-γ-CD, and HP-β-CD were found to be enantioselective 183 
towards duloxetine, being M-γ-CD and HP-β-CD those enabling to obtain Rs > 1. 184 
Although the optimum concentration was 0.5 % (w/v) for both M-γ-CD and HP-β-CD, 185 
HP-β-CD was selected as the best chiral selector as the enantiomeric impurity (R-186 
duloxetine) migrated before the active principle (S-duloxetine) unlike with M-γ-CD. The 187 
change in the enantiomer migration order has already been justified by our research group 188 
[20]. Once selected the most suitable chiral selector, the effect of the phosphate buffer 189 
concentration was studied from 50 to 250 mM, and its pH from 2.0 to 7.0. A 150 mM 190 
phosphate buffer (pH 3.0) was chosen as adequate in terms of current intensity and Rs. 191 
Temperature was studied from 15 to 35 ºC selecting 20 ºC as the optimum value as it 192 
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offered a good Rs and shorter migration times than 15 ºC. Since it was possible to increase 193 
the applied voltage from 15 to 30 kV, the total length of the capillary was increased to 194 
64.5 cm in order to improve the Rs. Finally, the effect of the injection volume and 195 
detection parameters was investigated to improve the method sensitivity. Injection times 196 
between 5 and 80 s were tested, selecting 20 s because it allowed obtaining a greater 197 
sensitivity without a significant Rs loss. With regard to the detector parameters optimal 198 
values were a response time of 1.0 s with a detection wavelength of 220 nm (bandwidth 199 
35 nm) including the reference wavelength. Under the optimized conditions, the 200 
enantioseparation of duloxetine was completed within 20 min with Rs of 2.1, using 0.1 201 
mg/ml as the amount of active principle to be analyzed for purity control (nominal value).  202 
 203 
3.2. Validation of the developed CE-UV method 204 
 The validation of the CE-UV method was carried out in terms of selectivity, 205 
linearity, accuracy, precision, and limits of detection (LOD) and quantitation (LOQ). To 206 
study the selectivity of the method, two different pharmaceutical formulations spiked with 207 
1 µg/mL of R-duloxetine and 100 µg/mL of S-duloxetine (nominal value) were analyzed. 208 
Interfering peaks were not found under these conditions.  209 
 As shown in Table 1, linearity was proven to be adequate in all cases as R2 values 210 
were ≥ 99 %, confidence interval for the slope did not include the zero value and 211 
confidence interval for the intercept included the zero value (for a 95 % confidence level). 212 
The Response Relative Factor (RRF) was between 0.8 and 1.2 as European Pharmacopeia 213 
dictates to demonstrate that R- and S-duloxetine responses are equal [21]. The results 214 
concluded (for a 95 % confidence level) that no matrix interferences existed. Therefore, 215 
and the external standard calibration method was employed to quantify the content of 216 
duloxetine in pharmaceutical formulations. 217 
10 
 
Accuracy was evaluated as the recovery obtained from six pharmaceutical 218 
samples replicates containing 100 µg/mL of duloxetine (according to labeled amount) 219 
spiked with 1 and 100 µg/mL of R- and S-duloxetine, respectively. Recovery values were 220 
acceptable as the 100 % value is included in all cases (see Table 1). Moreover, the 221 
precision was evaluated and RSD values (%) of migration times and corrected areas were 222 
acceptable as shown in Table 1. 223 
Finally, LOD and LOQ values were 0.2 µg/mL and 0.67 µg/mL, respectively. This 224 
LOD was experimentally verified (see Figure 1). According to this LOD and the nominal 225 
value described above, the method developed allowed the detection of impurities above 226 
a 0.2 % of R-duloxetine. Although this value is quite low, following the ICH guideline 227 
Q3B [3] this value must be lower than 0.1 % to apply it to determine impurities in 228 
pharmaceutical formulations, thus, the adaptation of this methodology to the use of MS 229 
detection was carried out.  230 
 231 
3.3 Modification of the CE-UV method to be compatible with MS detection 232 
Although chiral CE-UV methodologies can be transferred to a CE-MS system, 233 
this task is not always easy to achieve, and implies the modification of some parameters 234 
of the UV method. These modifications mainly include changes in the employed buffer 235 
since the ones employed in UV experiments are non-volatile and generate high currents 236 
intensities in the CE system [22]. For this reason, the non-compatible BGE employed in 237 
the UV experiments, phosphate buffer, was replaced with an also acidic but volatile 238 
medium, ammonium formate buffer. Different buffer pH and concentrations were tested, 239 
maintaining in all cases the chiral selector and its optimized concentration. A 150 mM 240 
ammonium formate buffer (pH 3.0) with 0.5 % (w/v) HP-β-CD was selected since these 241 
conditions originated the best Rs, yielding less than 50 µA of current intensity and making 242 
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possible the MS coupling. However, under these conditions the obtained Rs was not 243 
enough to perform an acceptable enantioseparation. Therefore, different parameters were 244 
modified such as the capillary length, the injection time of the sample and the temperature 245 
in order to improve the Rs. The total capillary length was enlarged from 64.5 cm to 104 246 
cm, sample injection time was reduced from 20 to 5 s and temperature had to be 247 
diminished from 20 to 15 ºC. Under these conditions, although migration times increased 248 
from 20 to 30 min, it could be possible to obtain a Rs good enough to perform the desired 249 
enantioseparation (Rs 2.7).  250 
To avoid source contamination and the low sensitivity derived from the use of a 251 
non-volatile chiral selector as HP-β-CD, a partial filling strategy was employed. A plug 252 
of 0.5 % (w/v) HP-β-CD in 150 mM ammonium formate buffer (pH 3.0) during 1 min 253 
(38 % of total capillary length) by applying 1 bar was selected as the best to obtain a 254 
satisfactory enantioresolution (Rs 2.5) and an adequate separation from the CD band. 255 
Under these conditions, the sensitivity in terms of S/N ratio improved up to 10 times, 256 
although the volume injected was about four times lower.  257 
 258 
3.4 Optimization of the CE-MS method 259 
Several analytical parameters of the MS system related with the ionization source, 260 
ionic optics, and analyzer were studied. Firstly, the sheath liquid composition was 261 
optimized to establish the electrical contact at the electrospray needle tip. A mixture of 262 
methanol:water (80:20, v:v) varying the percentage of formic acid content from 0.1 to 0.5 263 
% (v/v) was tested, selecting 0.1 % (v/v) as it offered the best S/N ratio. Sheath liquid 264 
flow rate was also optimized (from 1.3 to 5.3 µL/min) and 3.3 µL/min was chosen since 265 
it offered the best sensitivity with good stability of the ion current entering the MS system. 266 
In CE-MS the nebulizer pressure is an essential parameter to be optimized because the 267 
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suction effect is produced at high pressures resulting in a loss of Rs. Studied values were 268 
2, 3 and 7 psi, selecting 3 psi. With respect to the drying gas, a flow rate of 5 L/min at 269 
200 ºC was selected due to the better sensitivity originated. The effect of the applied 270 
voltage was evaluated (from 1500 to 6000 V) and better S/N was obtained at 4500 V. 271 
Under these conditions, the ion 298.1 m/z corresponding to the protonated form of 272 
duloxetine as well as its fragment of 153.8 m/z, were observed. This indicated that partial 273 
fragmentation of duloxetine occurred during the ionization process. Thus, the capillary 274 
exit from the ionic optics was optimized (from 0 to 140 V) trying to reduce this 275 
fragmentation. 57 V was the selected value since, although fragmentation of the ion m/z 276 
298.1 was inevitable, it fragmented the least.  277 
Finally, optimization of the MS2 experiments was performed employing the EIE 278 
of the transition from 298.1 to 153.8 m/z. The ICC was activated during the analysis to 279 
avoid the trap overloading and the target value was set at 100,000 because higher values 280 
originated a loss in mass precision. Maximum accumulation time was studied from 25 to 281 
300 ms, selecting 50 ms as it ensured the best proportionality between the areas of both 282 
enantiomers (when having different levels of concentration), with an average value of 3 283 
to obtain enough points to define the peaks. To favor the best entrapment, accumulation 284 
and ions fragmentation, more MS2 parameters had to be optimized. Isolation width (2, 4 285 
or 8 m/z) was set to 4 m/z since it allowed isolating the complete isotopic profile. Different 286 
combinations of the fragmentation parameters were tested such as voltage (from 0.2 to 287 
1.4 V), time (from 40 to 160 ms), width (from 4 to 40 m/z) and the “SmartFrag” option 288 
(activated or not) were tested. The best combination was 0.5 V, 40 ms, 10 m/z, 289 
respectively, with the “SmartFrag” option deactivated. These values allowed obtaining 290 
the highest fragmentation of the precursor ion 298.1 m/z without 153.8 m/z ion 291 
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fragmentation. Figure 2 shows the CE-MS2 EIE at 153.8 m/z and the MS2 spectra 292 
obtained for a racemic mixture of duloxetine (25 µg/mL). 293 
 294 
3.5 Analytical characteristics of the CE-MS2 method 295 
 The analytical characteristics were investigated in terms of linearity, precision and 296 
LOD and LOQ. As seen in Table 2, once again results show a perfect linearity in the 297 
studied range (R2 ≥ 99 %), confidence interval for the slope did not include the zero value 298 
and confidence interval for the intercept included the zero value in all cases. RRF value 299 
was 1.05 meaning that R-duloxetine response could be considered as S-duloxetine. For 300 
this CE-MS2 strategy, only the method repeatability was studied, as it is the most 301 
representative parameter of the precision. As Table 2 shows, precision values were quite 302 
better comparing them with those calculated for the CE-UV method (see Table 1). Figure 303 
3 shows the LOD obtained with the developed CE-MS2 method being this value 20 ng/mL 304 
(20 ppb) for R-duloxetine, reaching the lowest LOD value ever reported for the duloxetine 305 
enantiomeric impurity. The sensitivity has been improved 10 times when compared to the 306 
CE-UV method, enabling to detect 0.02 % of duloxetine enantiomeric impurity and, 307 
according to the ICH Q3B [3], the CE-MS2 method can be applied to the analysis of 308 
impurities. It is important to note that other methods described in the literature do not 309 
allow to meet the ICH requirements for the analysis of duloxetine. This highlights the 310 
importance of developing CE-MS2 methodologies in terms of achieving high sensitivity 311 
and selectivity, obtaining an unambiguous identification of the studied analytes. 312 
 313 
3.6 Comparative analysis of pharmaceutical formulations by both methodologies 314 
Four pharmaceutical formulations were analyzed by the developed methods. 315 
Enantiomeric impurity percentage, duloxetine content, and established content of 316 
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duloxetine are shown in Table 3. Values obtained by both methods were compared using 317 
statistical tests (F- and t-tests). There were not significant differences between the 318 
precision achieved by both methods (F-test), nor between the quantities obtained from 319 
the analysis of the drugs (t-test), as evidenced by the p-values, in all cases higher than 320 
0.05 (confidence level of 95 %). It is worth noted that none of the pharmaceutical 321 
formulations analyzed by the two chiral methodologies presented detectable amounts of 322 
the enantiomeric impurity and the S-duloxetine content was equivalent to the labeled 323 
content (the values of the established duloxetine content included the 100 % value in all 324 
cases). Figure 4 shows the electropherogram corresponding to the analysis of a 325 
pharmaceutical formulation by the CE-MS2 methodology. 326 
 327 
4. Concluding remarks 328 
 329 
The developed CE-MS2 method has been proven to be a valuable tool to enhance 330 
the sensitivity obtained for the determination of duloxetine enantiomers by CE-UV. An 331 
increase in the sensitivity up to 10 times was obtained, detecting 0.02 % of duloxetine 332 
impurity, which is suitable for the analysis of impurities as ICH guidelines dictates. Due 333 
to the fact that the Rs decreased when transferring the methodology from the CE-UV to 334 
the CE-MS system, some modifications had to be carried out, including an increase of the 335 
capillary length, which caused longer migration times (from 20 to 30 min). For the first 336 
time, duloxetine pharmaceutical formulations have been analyzed and the results 337 
indicated that duloxetine impurity was not detectable and that the duloxetine content was 338 
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Figure legends 408 
 409 
Figure 1. CE-UV electropherogram corresponding to the LOD of R-duloxetine (0.2 410 
µg/mL) in the presence of 100 µg/mL of S-duloxetine. Experimental conditions: BGE, 411 
0.5 % (w/v) of HP-β-CD in 150 mM phosphate buffer (pH 3.0); uncoated fused-silica 412 
capillary, 64.5 cm (56 cm effective length) x 50 µm I.D.; temperature, 20 ºC; voltage, 30 413 
kV; hydrodynamic injection, 50 mbar x 20 s; UV detection at 220, 4 nm (reference 414 
wavelength: 375, 100 nm). * Unknown impurity. 415 
Figure 2. CE-MS2 EIE for a 25 µg/mL racemic mixture of duloxetine under the optimized 416 
conditions and the corresponding MS2 spectra for the peaks. Experimental conditions: 417 
BGE, 150 mM ammonium formate buffer (pH 3.0); PFT, 0.5 % (w/v) of HP-β-CD in 418 
BGE applying 1 bar during 1 min; uncoated fused-silica capillary, 104 cm x 50 µm I.D.; 419 
temperature, 15 ºC; voltage, 30 kV; hydrodynamic injection, 50 mbar x 5 s; sheath liquid, 420 
3.3 µL/min of 80:20 (v/v) methanol/water with 0.1 % (v/v) of formic acid; nebulizer and 421 
drying gas, 3 psi N2 and 5 L/min N2 at 200 ºC; ESI+ at -4.5 kV with an end plate of -500 422 
V; capillary exit, 57 V; EIE, 153.8 m/z (MS2 transition from 298.1 m/z)  fragmentation 423 
by collision-induced dissociation with He, 0.5 V for 40 ms to a fragmentation width of 424 
10 m/z. 425 
Figure 3. CE-MS2 EIE corresponding to the LOD of R-duloxetine (0.02 µg/mL) in the 426 
presence of 100 µg/mL S-duloxetine. Experimental conditions as in Figure 2. * Unknown 427 
impurity. 428 
Figure 4. CE-MS2 EIE corresponding to a pharmaceutical formulation with a 429 
concentration of 100 µg/mL of S-duloxetine according to the labeled content. 430 
Experimental conditions as in Figure 2. * Unknown impurity. 431 
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